Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets-Reference-Cited by-同舟云学术

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets

Published:2020-02 Issue:2 Volume:26 Page:143-153
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Cannon Anthony J.¹,Bargiota Alexandra²,Billings Liana³,Hunt Barnaby⁴,Leiter Lawrence A.⁵,Malkin Samuel⁴,Mocarski Michelle⁶,Ranthe Mattis Flyvholm⁷,Schiffman Alisa⁶,Doshi Ankur⁸

Affiliation:

1. Endocrinology, Jefferson Health NJ, Voorhees, New Jersey.

2. Department of Endocrinology and Metabolic Diseases, University Hospital of Larissa, Larissa, Greece.

3. NorthShore University HealthSystem, Skokie, Illinois, and University of Chicago Pritzker School of Medicine, Chicago, Illinois.

4. Ossian Health Economics and Communications, Basel, Switzerland.

5. Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Ontario.

6. Novo Nordisk, Plainsboro, New Jersey

7. Novo Nordisk A/S, Søborg, Denmark.

8. PrimeCare Medical Group, Houston, Texas.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes;Diabetology;2023-10-13

2. IDegLira for type 2 diabetes: a systematic review and meta-analysis;Endocrine;2023-09-28

3. Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations;Diabetes Therapy;2023-09-22

4. A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico;PharmacoEconomics - Open;2023-07-15

5. Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression;Journal of Comparative Effectiveness Research;2021-04